Roadshow
ENERGI-Platform
In the central nervous system (CNS) field, Energenesis is advancing ENERGI-F705PD tablet a disease-modifying therapy in Phase I trial, designed to prevent protein aggregation and reduce oxidative stress. The drug has demonstrated neuroprotective effects in preclinical models of Parkinson’s disease and Alzheimer’s disease. In the wound healing area, the ENERGI approach boosts cellular ATP to promote cell migration and wound healing. The pipelines include ENERGI-F703DFU Gel, a Phase III project for treating diabetic foot ulcers (DFUs), and ENERGI-F703EB Cream, an orphan drug candidate for Epidermolysis Bullosa (EB), granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation from the U.S. FDA, and Orphan Designation from the EMA.
Join us at BIO 2025, June 16-19 in Boston, where Energenesis Biomedical Co., Ltd. will be showcasing our cutting-edge solutions and services. We can't wait to connect with you to discuss how we're shaping the future of biotechnology. Find us at Booth 1645. See you there!
#BIO2025#TAIWAN PAVILION
Additionally, ENERGI-F701 Tonic targets hair loss through anti-senescence activity. In a Phase II trial, it demonstrated a fast-acting effect, with significant improvement observed within four weeks. With a strong passion for developing treatments, Energenesis is committed to advancing novel therapies for challenging diseases in neurodegenerative disorders and the areas of unmet medical needs.
- Established 2012
- Company Energenesis Biomedical Co., Ltd.
- Telephone +886-2-2627-0835
- Email shelly@energenesis-biomedical.com
- Address 6F.-3, No.21, Ln.583, Ruiguang Rd., Neihu Dist., Taipei 11492, Taiwan
Energenesis Biomedical (Taiwan Listed Company) is a biotechnology company founded in 2012 and listed on the Taiwan Stock Exchange in 2023. Energenesis is focused on developing innovative therapeutics based on its proprietary ENERGI-Platform, which uses small molecule drugs to enhance cellular energy (ATP) and activate self-healing mechanisms. In the central nervous system (CNS) field, Energenesis is advancing ENERGI-F705PD tablet a disease-modifying therapy in Phase I trial, designed to prevent protein aggregation and reduce oxidative stress.